Vebreltinib plus chemotherapy for first-line MET-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted drug, vebreltinib, combined with standard chemotherapy as the first treatment for advanced non-small cell lung cancer that has a specific marker called MET overexpression. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with advanced non-small cell lung cancer (stage IV or recurrent) that cannot be removed by surgery or treated with radiation.
- You have not yet received any treatment for your advanced lung cancer.
- Your tumor shows high levels of a protein called MET (confirmed by a lab test).
- You do not have certain other gene changes (like EGFR or ALK) that can be targeted by other drugs.
- You are generally well enough to carry out daily activities (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
This trial tests a targeted drug called vebreltinib given before surgery to people with a specific type of non-small cell lung cancer that has a MET gene change. The goal is to see if it can shrink the tumor enough to make surgery more successful.
This trial compares a new drug combination (RC148 plus chemotherapy) with a standard immunotherapy (tislelizumab) plus chemotherapy for people with a common type of lung cancer. It tests whether the new combination works better as a first treatment for advanced cancer.
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
This trial tests a new targeted therapy (vebreltinib plus PLB1004) against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific change (EGFR mutation) and MET protein, and has stopped responding to earlier EGFR treatment.
Hear when a new Lung Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.